{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:12:14Z","timestamp":1773317534937,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: To describe the outcomes of patients with refractory noninfectious ocular inflammatory diseases who underwent treatment with repository corticotropin injection (RCI). Methods: A retrospective cohort study was conducted. Patients who failed treatment with corticosteroids and were subsequently treated with RCI were included. Primary outcome measures were intraocular inflammatory activity, intraocular pressure (IOP), and the development of complications. Results: A total of 19 eyes from 10 patients were included. Most of the patients were women (70.0%) and the median age at presentation was 49.0 years (30.0\u201384.0 years). The ocular diagnoses were anterior\/intermediate uveitis, intermediate\/posterior uveitis, panuveitis, ocular cicatricial pemphigoid, and anterior scleritis. Seventeen (89.5%) eyes had active disease. The median duration of RCI treatment was 16.0 months (6.0\u201328.0 months). Nine (90.0%) patients, representing 17 (89.5%) eyes, achieved disease inactivity and remained quiescent at the last visit. No patient was on systemic corticosteroids at the last evaluation. The mean IOP was lower under RCI than corticosteroid at one month (16.0 mmHg \u00b1 6.1 vs. 20.8 mmHg \u00b1 9.5, p = 0.033) and four months (15.6 mmHg \u00b1 2.9 vs. 17.8 mmHg \u00b1 3.7, p = 0.046); however, the overall difference was not significant (16.2 mmHg \u00b1 1.1 vs. 17.3 mmHg \u00b1 1.8, p = 0.057). Incidence rates were the highest for posterior subcapsular cataracts (44.4% per eye-year). Relative risk analysis (RR) showed a 40.0% risk reduction for cystoid macular edema (RR = 0.60, p = 0.054). Conclusions: RCI may be an alternative treatment for refractory noninfectious ocular inflammatory diseases in patients who have failed treatment with corticosteroids.<\/jats:p>","DOI":"10.3390\/jcm14217785","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:30:27Z","timestamp":1762198227000},"page":"7785","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repository Corticotropin Therapy for Refractory Noninfectious Inflammatory Ocular Diseases"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-1845","authenticated-orcid":false,"given":"Christian","family":"Nieves-R\u00edos","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2610-4019","authenticated-orcid":false,"given":"Ricardo A.","family":"Murati Calderon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-6121","authenticated-orcid":false,"given":"Armando L.","family":"Oliver","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/09273948.2022.2034166","article-title":"Mycophenolate versus Methotrexate in Non-infectious Ocular Inflammatory Disease: A Systematic Review and Meta-Analysis","volume":"31","author":"Karam","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/ICO.0000000000002771","article-title":"Repository Corticotropin Injection as an Alternative Treatment for Refractory Ocular Mucous Membrane Pemphigoid","volume":"41","author":"Sharon","year":"2022","journal-title":"Cornea"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/aos.14702","article-title":"Management of repository corticotropin injection therapy for non-infectious uveitis: A Delphi study","volume":"99","author":"Nguyen","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1100\/tsw.2010.173","article-title":"The melanocortin system in control of inflammation","volume":"10","author":"Catania","year":"2010","journal-title":"Sci. World J."},{"key":"ref_7","unstructured":"Mallinckrodt (2018). Acthar Gel (Repository Corticotropin Injection) [Prescribing Information], Mallinckrodt. Available online: https:\/\/www.acthar.com\/Static\/pdf\/Acthar-PI.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/jop.2020.0039","article-title":"Use of Adrenocorticotropic Hormone in Ophthalmology","volume":"36","author":"Crane","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1999.tb08662.x","article-title":"The proopiomelanocortin system","volume":"885","author":"Hadley","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.smim.2015.02.003","article-title":"ACTH: The forgotten therapy","volume":"27","year":"2015","journal-title":"Semin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wang, S., Kahale, F., Naderi, A., Surico, P.L., Yin, J., Dohlman, T., Chen, Y., and Dana, R. (2024). Therapeutic Effects of Stimulating the Melanocortin Pathway in Regulating Ocular Inflammation and Cell Death. Biomolecules, 14.","DOI":"10.3390\/biom14020169"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.06.022","article-title":"Targeting melanocortin receptors as potential novel therapeutics","volume":"111","author":"Getting","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajoc.2016.09.004","article-title":"Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent","volume":"4","author":"Agarwal","year":"2016","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.18502\/jovr.v16i2.9086","article-title":"Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection","volume":"16","author":"Anesi","year":"2021","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jdcr.2020.02.034","article-title":"Ocular cicatricial pemphigoid treated with intramuscular corticotropin injections","volume":"6","author":"Chen","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/09273948.2021.1884887","article-title":"Outcomes of Repository Corticotropin Gel for Ocular Sarcoidosis","volume":"30","author":"Oh","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_17","first-page":"509","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data","volume":"140","author":"Jabs","year":"2005","journal-title":"Results First Int. Workshop. Am. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/IAE.0b013e3181ef8786","article-title":"Idiopathic and secondary epiretinal membranes: Do they differ in terms of morphology? An optical coherence tomography-based study","volume":"31","author":"Yazici","year":"2011","journal-title":"Retina"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2010.04.031","article-title":"Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis","volume":"150","author":"Loh","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1089\/jop.2018.0090","article-title":"Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States","volume":"35","author":"Nelson","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/OPTH.S4033","article-title":"Cystoid macular edema","volume":"2","author":"Rotsos","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.ajoc.2019.100502","article-title":"Adrenocorticotropic hormone gel for patients with non-infectious uveitis","volume":"15","author":"Sharon","year":"2019","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ajoc.2018.03.018","article-title":"Adrenocorticotropic hormone analogue as novel treatment regimen in ocular cicatricial pemphigoid","volume":"10","author":"Sharon","year":"2018","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12348-024-00428-8","article-title":"Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases","volume":"14","author":"Yavari","year":"2024","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_26","unstructured":"Chu, D., Nguyen, Q., and Scales, D. (2025, January 11). An Open-Label, Multicenter, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH Gel in Patients with Scleritis: The ATLAS Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03465111."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7785\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:53:54Z","timestamp":1762199634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":26,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217785"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217785","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,2]]}}}